New PET tracer could spot Hard-to-Find neuroendocrine cancers
NCT ID NCT07132645
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-phase trial is testing a radioactive tracer called FAPI-04 to see how well it lights up high-grade neuroendocrine tumors on PET/CT scans. The study will enroll 30 adults with these aggressive tumors to measure where the tracer goes in the body and how much it accumulates in cancer compared to normal tissues. The goal is to determine if this imaging method could help doctors better detect and monitor these cancers.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Gallium Ga 68-DOTA-FAPI-04 (a radioactive tracer for PET scans)
What this could lead to
If successful, this could lead to a more accurate imaging method for detecting high-grade neuroendocrine tumors, potentially improving diagnosis and treatment planning.
What could go wrong
This is a very early (Phase 1) exploratory study with only 30 participants. It is designed to see where the tracer goes in the body, not to prove it improves outcomes. The tracer may not reliably distinguish tumors from normal tissue.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Michigan Comprehensive Cancer Center
RECRUITINGAnn Arbor, Michigan, 48109, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact